OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lincoln Pharmaceuticals OCF Yield % Related Terms
Lincoln Pharmaceuticals OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lincoln Pharmaceuticals OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Lincoln Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lincoln Pharmaceuticals (NSE:LINCOLN) has a OCF Yield % of 8.56 as of Jul. 07, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lincoln Pharmaceuticals and its competitors. Over the past decade, Lincoln Pharmaceuticals' OCF Yield % has ranged from 8.56 to 8.56. According to the industry distribution chart, Lincoln Pharmaceuticals ranks #250 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Lincoln Pharmaceuticals' OCF Yield % too high?
Lincoln Pharmaceuticals' current OCF Yield % is 8.56. Over the past 10 years, this metric has ranged from a low of 8.56 to a high of 8.56. The Drug Manufacturers industry median OCF Yield % is 3.41. Lincoln Pharmaceuticals' value of 8.56 is 151% above this industry median. Based on the distribution chart, Lincoln Pharmaceuticals ranks #250 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lincoln Pharmaceuticals has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lincoln Pharmaceuticals ranks #250 out of 1007 companies for OCF Yield %. This places Lincoln Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.41. Lincoln Pharmaceuticals' value of 8.56 is 151% above this benchmark. Historically, Lincoln Pharmaceuticals' own OCF Yield % has ranged from 8.56 to 8.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.41, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lincoln Pharmaceuticals's current OCF Yield % of 8.56 is 151% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lincoln Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lincoln Pharmaceuticals's current OCF Yield % is 8.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹706.28, compared to a current price of ₹614.60 — trading 13% below its estimated fair value. The current OCF Yield % is 8.56 and 151% above the Drug Manufacturers industry median of 3.41. Lincoln Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current OCF Yield % is 8.56 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹614.60 is trading 13% below its estimated GF Value™ of ₹706.28.
GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:LINCOLN:
OCF Yield %: 8.56
GF Value™: ₹706.28 vs. price of ₹614.60 (13% below fair value)
Industry Position: 151% above the Drug Manufacturers median (#250 of 1007)
No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
85GF Score
Get the complete analysis for NSE:LINCOLN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LINCOLN has been successfully added to your 
